A new clinical trial at the University of Chicago Medicine is evaluating the combination of 177Lu-DOTATATE with fulvestrant in patients with advanced pancreatic neuroendocrine tumors (pNETs). This phase I, open-label study aims to assess the safety and preliminary tumor response of the investigational treatment combination. Fulvestrant is a hormone therapy used to treat certain kinds … Continue reading New Trial to Evaluate Combination of Fulvestrant and 177Lu-DOTATATE in Advanced Pancreatic Neuroendocrine Tumors